Quad elvitegravir/cobicistat/emtricitabine/tenofovir: Additional Phase II data

Additional data from the double-blind Phase II GS-US-236-0104 trial in 71 treatment-naïve patients with HIV RNA levels >=5,000 copies/mL showed that the proportion of patients who achieved HIV RNA levels <50 copies/mL at 48 weeks was 90% for once-daily Quad vs. 83% for Atripla emtricitabine/tenofovir/efavirenz. Data were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston. Gilead previously reported that the Quad regimen was non-inferior to Atripla on the primary endpoint of the proportion of patients achieving HIV RNA levels <50 copies/mL at 24 weeks (see BioCentury, Jan. 11 & Feb. 22). ...